UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Neuroprotective Effects of 3,6′-Disinapoyl Sucrose Through Increased BDNF Levels and CREB Phosphorylation via the CaMKII and ERK1/2 Pathway

Journal of molecular neuroscience, 2014-08, Vol.53 (4), p.600-607

2014

Link zum Volltext

Verfügbarkeit prüfen

A potential peptide therapeutic derived from the juxtamembrane domain of the epidermal growth factor receptor

PloS one, 2012-11, Vol.7 (11), p.e49702-e49702

2012

Link zum Volltext

Verfügbarkeit prüfen

The regulatory role of the juxtamembrane region in the activity of the epidermal growth factor receptor

Biochemical Society transactions, 2012-02, Vol.40 (1), p.195

Boran, Aislyn D W

2012

Link zum Volltext

Verfügbarkeit prüfen

Recovering protein-protein and domain-domain interactions from aggregation of IP-MS proteomics of coregulator complexes

PLoS computational biology, 2011-12, Vol.7 (12), p.e1002319-e1002319

2011

Link zum Volltext

Verfügbarkeit prüfen

Genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancer identified by systems therapeutics analyses

Molecular oncology, 2019-08, Vol.13 (8), p.1725-1743

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT025-CT025

2021

Link zum Volltext

Verfügbarkeit prüfen

Identification of new G beta gamma interaction sites in adenylyl cyclase 2

Cellular signalling, 2011-09, Vol.23 (9), p.1489-1495

2011

Link zum Volltext

Verfügbarkeit prüfen

Identification of new Gβγ interaction sites in adenylyl cyclase 2

Cellular signalling, 2011-09, Vol.23 (9), p.1489-1495

2011

Link zum Volltext

Verfügbarkeit prüfen

Systems approaches to polypharmacology and drug discovery

Current opinion in drug discovery & development, 2010-05, Vol.13 (3), p.297

2010

Link zum Volltext

Verfügbarkeit prüfen

Systems Pharmacology

The Mount Sinai journal of medicine, 2010-07, Vol.77 (4), p.333-344

2010

Link zum Volltext

Verfügbarkeit prüfen

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature medicine, 2023-05, Vol.29 (5), p.1103-1112

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of JDQ443 in KRAS G12C -mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS9158-TPS9158

2023

Link zum Volltext

Verfügbarkeit prüfen

RARE-11. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED LOW-GRADE GLIOMA (LGG)

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi238-vi239

2018

Link zum Volltext

Verfügbarkeit prüfen

ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)

Neuro-oncology (Charlottesville, Va.), 2019-11, Vol.21 (Suppl 6), p.vi19-vi20

2019

Link zum Volltext

Verfügbarkeit prüfen

KontRASt-02: A phase III trial investigating the efficacy and safety of the KRAS G12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C -mutated NSCLC

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS9144-TPS9144

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT120-CT120

2019

Link zum Volltext

Verfügbarkeit prüfen

Dabrafenib plus trametinib in patients with BRAF V600E -mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

The lancet oncology, 2020-09, Vol.21 (9), p.1234

2020

Link zum Volltext

Verfügbarkeit prüfen

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

The lancet oncology, 2020-09, Vol.21 (9), p.1234-1243

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT048: A Phase II trial of JDQ443 in KRAS G12C- mutated NSCLC with PD-L1 expression <1% or PD-L1 expression≥1% and an STK11 co-mutation

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT048-CT048

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.187-187

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract C111: Safety profile and tumor response in patients with refractory superficial cancers treated with HF10, an oncolytic replication-competent HSV-1-derived intratumoral injectable, as monotherapy and combined with ipilimumab

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.C111-C111

2015

Link zum Volltext

Verfügbarkeit prüfen

ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)

Neuro-oncology (Charlottesville, Va.), 2019-11, Vol.21 (Supplement_6), p.vi19-vi20

2019

Link zum Volltext

Verfügbarkeit prüfen

Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9543-9543

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(10)
Science & Technology
(9)
Life Sciences & Biomedicine
(8)
Gene Expression
(6)
Cancer
(5)
Tumors
(5)
Biochemistry & Molecular Biology
(4)
Cancer Therapies
(4)
Female
(4)
Kinases
(4)
Lung Cancer
(4)
Mutation
(4)
Oncology
(4)
Protein Binding
(4)
Proteins
(4)
Signal Transduction
(4)
Amino Acid Sequence
(3)
Animals
(3)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(3)
Cell Biology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neuroprotective Effects of 3,6′-Disinapoyl Sucrose Through Increased BDNF Levels and CREB Phosphorylation via the CaMKII and ERK1/2 Pathway

A potential peptide therapeutic derived from the juxtamembrane domain of the epidermal growth factor receptor

The regulatory role of the juxtamembrane region in the activity of the epidermal growth factor receptor

Recovering protein-protein and domain-domain interactions from aggregation of IP-MS proteomics of coregulator complexes

Genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancer identified by systems therapeutics analyses

Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)

Identification of new G beta gamma interaction sites in adenylyl cyclase 2

Identification of new Gβγ interaction sites in adenylyl cyclase 2

Systems approaches to polypharmacology and drug discovery

Systems Pharmacology

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

A phase II trial of JDQ443 in KRAS G12C -mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation

RARE-11. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED LOW-GRADE GLIOMA (LGG)

ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)

KontRASt-02: A phase III trial investigating the efficacy and safety of the KRAS G12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C -mutated NSCLC

Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

Dabrafenib plus trametinib in patients with BRAF V600E -mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

Dabrafenib plus trametinib in patients with BRAF V600E -mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

Abstract CT048: A Phase II trial of JDQ443 in KRAS G12C- mutated NSCLC with PD-L1 expression <1% or PD-L1 expression≥1% and an STK11 co-mutation

Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial

Abstract C111: Safety profile and tumor response in patients with refractory superficial cancers treated with HF10, an oncolytic replication-competent HSV-1-derived intratumoral injectable, as monotherapy and combined with ipilimumab

ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)

Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma

Suchergebnisse filtern